The BCG vaccine and SARS-CoV-2: Could there be a beneficial relationship?

Publication date: Sep 30, 2024

The COVID-19 disease continues to cause complications and deaths worldwide. Identifying effective immune protection strategies remains crucial to address this ongoing challenge. The Bacillus Calmette-GucE9rin (BCG) vaccine, developed initially to prevent pulmonary tuberculosis, has gained relevance due to its ability to induce cross-protection against other pathogens of the airways. This review summarizes research on the immunological protection provided by BCG, along with its primary clinical and therapeutic uses. It also explores the immunological features of COVID-19, the mechanisms implicated in host cell death, and its association with chronic pulmonary illnesses such as tuberculosis, which has led to complications in diagnosis and management. While vaccines against COVID-19 have been administered globally, uncertainty still exists about its effectiveness. Additionally, it is uncertain whether the utilization of BCG can regulate the immune response to pathogens such as SARS-CoV-2.

Concepts Keywords
Airways BCG
Death COVID-19
Host Immune response
Tuberculosis Tuberculosis
Vaccine Vaccine

Semantics

Type Source Name
drug DRUGBANK BCG vaccine
disease MESH COVID-19
disease MESH complications
disease MESH pulmonary tuberculosis
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH uncertainty
disease IDO immune response

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *